Human Patents (Class 435/366)
  • Publication number: 20140154745
    Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cells culture comprising the cells, the biological substance and the cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Gerben Meile Zijlstra, Robert Patrick Hoff, Jacob Schilder
  • Publication number: 20140154802
    Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.
    Type: Application
    Filed: February 10, 2014
    Publication date: June 5, 2014
    Applicant: Viacyte, Inc.
    Inventors: Allan J. Robins, Thomas C. Schulz
  • Publication number: 20140154752
    Abstract: Glycoside hydrolases having at least two different hydrolytic activities are provided. In one embodiment, an isolated recombinant hydrolase having at least two activities selected from a group including asparagine derivatives, glutamine derivatives, and histidine derivatives is provided. Further, a method of generating free sugars from a mixture comprising asparagine derivatives, glutamine derivatives, and histidine derivatives is provided.
    Type: Application
    Filed: May 1, 2012
    Publication date: June 5, 2014
    Applicants: Sandia Corporation, The Regents of the University of California
    Inventors: Zhiwei Chen, Gregory D. Friedland, Swapnil R. Chhabra, Dylan C. Chivian, Blake A. Simmons
  • Publication number: 20140155290
    Abstract: Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided.
    Type: Application
    Filed: February 6, 2014
    Publication date: June 5, 2014
    Applicant: AMGEN INC.
    Inventor: Christopher Kenyon Crowell
  • Patent number: 8741638
    Abstract: Methods for the maximizing parameter of the in vitro growth and expansion of mammalian cells, specifically postpartum-derived cells in containers such as roller bottles is described. Methods of optimizing growth rate and cell yield in such culture systems are provided. The methods are particularly adapted for human postpartum-derived cells, such as umbilicus-derived cells.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 3, 2014
    Assignee: DePuy Synthes Products, LLC
    Inventor: Alexander M. Harmon
  • Patent number: 8741653
    Abstract: The present invention is directed to a modified poxvirus vector that allows for the generation of recombinant poxviruses by a single recombination event. A modified poxvirus vector comprising at least one reporter gene located between two flanking sequences for homologous recombination is disclosed. Furthermore, a host cell comprising said vector and a method for the generation of recombinant poxviruses using said vector are provided.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: June 3, 2014
    Assignee: Emergent Product Development GmbH
    Inventors: Sonja Leyrer, Katja Fischer
  • Patent number: 8741640
    Abstract: A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: June 3, 2014
    Inventors: Hong Gao, Zhenglun Zhu
  • Patent number: 8741648
    Abstract: Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34+ hematopoietic cells, such as human CD34+ blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: June 3, 2014
    Assignee: Cellular Dynamics International, Inc.
    Inventors: Deepika Rajesh, Amanda Mack
  • Patent number: 8742200
    Abstract: This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: June 3, 2014
    Assignee: Advanced Cell Technology, Inc.
    Inventors: Young Gie Chung, Robert Lanza, Irina V. Klimanskaya
  • Patent number: 8741277
    Abstract: The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: June 3, 2014
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Michael B. Chancellor, Johnny Huard, Christopher C. Capelli, Zhuqing Qu
  • Patent number: 8741340
    Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: June 3, 2014
    Assignee: NsGene A/S
    Inventors: Philip Kusk, Lars Ulrik Wahlberg
  • Patent number: 8741641
    Abstract: An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as ovarian cancer, and a cell growth inhibitor. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of at least one alteration of a gene existing in a chromosomal region 2q14. 2, 3p24. 1, 3q26. 2, 3q29, 4q34. 2, 6q23, 9p21. 3, 11q13. 3, 13q22.1, 13q33. 1, 13q33. 3, 15q12, 15q15. 1, 17p12, 17p13. 1, 17p13. 3, 18q21. 1, 18q21. 2, 18q21. 31, 18q21. 32, 18q21. 33, 18q23, 20q13. 13, 20q13. 2, 20q13. 31, 20q13. 33, Xp11. 23, Xp13.1, Xp13. 3, Xp26. 2, Xp26. 3, or Xq28 in the specimen.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: June 3, 2014
    Assignees: FUJIFILM Corporation, National University Corporation Tokyo Medical and Dental University
    Inventors: Johji Inazawa, Issei Imoto, Ryoko Kikuchi
  • Publication number: 20140147920
    Abstract: Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 29, 2014
    Applicants: The Regents of the University of California, Northwestern University
    Inventors: Frank L. Meyskens, JR., Richard B. Silverman, Sun Yang, Haitao Ji, Fengtian Xue, Thomas L. Poulos
  • Publication number: 20140147453
    Abstract: The present invention relates to a fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhFas-1 domain which is the fourth fas-1 domain of ?ig-h3 lacking H1 and H2 regions; b) a MMP (Matrix metalloproteinase) substrate; and c) a peptide comprising RGD motif and an use thereof for preventing and treating inflammatory disease. The fusion peptide of the present invention inhibits expension of rheumatoid arthritis by adhesion and migration of sinoviocytes and may be used for preventing or treating inflammatory disease by inhibiting infiltration of immune cells.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 29, 2014
    Applicant: Kyungpook National University Industry-Academic Cooperation Foundation
    Inventors: Young Mo Kang, In San Kim, Jin Hee Kang, Keum Hee Sa
  • Publication number: 20140147419
    Abstract: Provided is a step-wise method of forming an engineered construct. Various embodiments include inducing differentiation of progenitor cells, such as embryonic stem cells; expanding the differentiated progenitor cells; combining the expanded progenitor cells and a biocompatible scaffold comprising a matrix material; and incubating the progenitor cells and the biocompatible scaffold so as to form a bone tissue module.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 29, 2014
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gordana V. Novakovic, Darja Marolt
  • Publication number: 20140147494
    Abstract: An aligned polymer article including substrates, wherein the substrates are not covalently bonded to the aligned collagen and a method of forming such articles wherein substrates are mixed with a polymer in solution to form a polymer-substrate mixture. The mixture is placed in an electrochemical cell and a voltage is applied to the cell generating a pH gradient, wherein the polymer aligns in the cell and migrates to the isoelectric plane of the polymer solution.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 29, 2014
    Inventor: Xingguo CHENG
  • Publication number: 20140147919
    Abstract: IDH1 gene-defective cell lines (e.g., IDH1R132H heterozygous) have been made from a robust cell line, HCT116. The IDH1 gene-defective cell lines can be used to determine the effect of IDH1R132H on cell biology, tumorigenesis, and cellular metabolic profiles. These cell lines can be used to test potential therapeutic targets and to screen potential therapeutic agents. Kits and xenografts are also contemplated.
    Type: Application
    Filed: October 25, 2011
    Publication date: May 29, 2014
    Inventors: Hai Yan, Darell Bigner, Christopher Gentry Duncan
  • Publication number: 20140147463
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: May 29, 2014
    Applicant: CRUCELL HOLLAND B.V.
    Inventors: KATARINA RADOSEVIC, JEROME H. H. V. CUSTERS, JORT VELLINGA, MYRA N. WIDJOJOATMODJO
  • Publication number: 20140147422
    Abstract: A method of deriving isolated stem cells including: implanting a matrix in a wound site of a living organism; allowing cells to infiltrate the matrix; removing the matrix containing the infiltrated cells from the wound site; and removing the infiltrated cells from the matrix to provide isolated stem cells. Stem cells produced by this process, stem cells with certain characteristics, and methods for treating wounds using these stem cells are provided.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 29, 2014
    Applicant: Embro Corporation
    Inventors: Vance D. Fiegel, David R. Knighton
  • Patent number: 8734827
    Abstract: A bioengineered IVD for disc replacement has been developed that has mechanical and structural support characteristics similar to those of native IVD. Extracellular matrix (ECM) provides support to living cell components and interacts with the living cellular components during the fabrication process without introducing toxicity. The composition can be produced from both natural or synthetic source but preferably natural and induced to self-assemble or reconstitute into its solid form under conditions that are mild enough to support cellular survival and growth. The cells induce a volume change of the structures, leading to changes in dimension, ECM density, cell density, mechanical property and stability, etc. The extent of the change in volume of the composition can be precisely controlled by factors such as the density of the ECM, the density of the living cells, the timing for interaction and the serum concentration. Increased structural support is provided by crosslinking.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: May 27, 2014
    Assignee: University of Hong Kong
    Inventors: Barbara Pui Chan, Kenneth Man-Chee Cheung, Danny Chan, Godfrey Chi-Fung Chan, Ting Yan Hui
  • Patent number: 8735148
    Abstract: Disclosed herein are activated NK cells that exhibit durable and prolonged activity in the absence of the activating agent and retain their activated state after preservation. Methods of administrating the NK cells to a patient do not require co-administration of the activating agent, and thus, pharmaceutical compositions comprising the NK cells may remain substantially free of the activating agent.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: May 27, 2014
    Assignee: UCL Business PLC
    Inventor: Mark Lowdell
  • Patent number: 8735149
    Abstract: Provided is a method for directing differentiation of neural progenitors with a caudal and ventral specification into motor neurons including culturing neural progenitors in a culturing medium including a basic medium supplemented by at least one inhibitor of the Notch signaling pathway whereby the neural progenitors differentiate into postmitotic motor neurons. The resulting motor neurons may be used for drug development, as carriers, e.g. for gene therapy of protein delivery as well as for transplantation for the purpose of treating a motor neuron disease.
    Type: Grant
    Filed: April 5, 2009
    Date of Patent: May 27, 2014
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Benjamin Reubinoff, Etti Ben Shushan, Michal Aharonowiz
  • Publication number: 20140141444
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • Publication number: 20140141045
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Application
    Filed: November 15, 2013
    Publication date: May 22, 2014
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • Publication number: 20140141445
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • Patent number: 8728815
    Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: May 20, 2014
    Assignee: University of Southern California
    Inventor: Valter Longo
  • Patent number: 8728809
    Abstract: Stem cells are proliferated with the application of acoustic pressure waves, including cambium cells of periosteum treated in-vivo with acoustic pressure waves. Following harvesting and viability assessment of in-vivo or in-vitro proliferated stem cells, acoustic pressure waves are applied to enhance in-vivo or in-vitro differentiation either before or after implantation of the stems cells to an organism. Acoustic pressure waves also stimulate an implantation site to enhance viability and to grow desired tissue.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: May 20, 2014
    Assignee: Sanuwave, Inc.
    Inventors: Iulian Cioanta, Christopher M. Cashman
  • Patent number: 8728812
    Abstract: Certain embodiments disclosed herein are directed to a method of producing pancreatic cells or pancreatic cell precursors by exposing human embryonic stem cells to an effective amount of at least one compound listed in Table I to differentiate the human embryonic stem cells into the pancreatic cells or the pancreatic cell precursors. Kits and pancreatic cell lines produced using the methods are also described.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: May 20, 2014
    Assignees: President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: Shuibing Chen, Douglas A. Melton, Malgorzata Borowiak, Julia Lamenzo, Stuart L. Schreiber, Lee F. Peng, Lance Davidow, Kelvin Lam, Lee L. Rubin
  • Patent number: 8728808
    Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: May 20, 2014
    Assignee: Intrexon Corporation
    Inventors: Tarlochan Singh Dhadialla, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, Jr., Mohan Philip
  • Publication number: 20140134727
    Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
    Type: Application
    Filed: November 5, 2013
    Publication date: May 15, 2014
    Applicant: VIACYTE, INC.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
  • Publication number: 20140137274
    Abstract: PROBLEM There are provided induced malignant stem cells capable of in vitro proliferation that are useful in cancer research and drug discovery for cancer therapy, as well as processes for production thereof, cancer cells derived from these cells, and applications of these cells.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 15, 2014
    Applicants: LSIP, LLC, National Cancer Center
    Inventors: National Cancer Center, LSIP, LLC
  • Publication number: 20140134729
    Abstract: Synthetic surfaces suitable for culturing stem cell derived oligodendrocyte progenitor cells contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived oligodendrocyte progenitor cells in chemically defined media.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 15, 2014
    Applicant: GERON CORPORATION
    Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
  • Publication number: 20140134604
    Abstract: Replicons of genotype 6 hepatitis C virus (HCV) are provided. These replicons contain adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 6 replicons and methods of using these replicons to screen antiviral agents are also provided.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 15, 2014
    Inventors: Guofeng Cheng, William E. Delaney, IV, Betty Peng, Mei Yu
  • Publication number: 20140134136
    Abstract: The invention provides compositions for inducing expression in hair cells, and provides methods of using these compositions for modulating cochlear expression. Such compositions are further useful in treatment of sensorineural hearing loss, e.g., increasing proliferation or survival of mechanosensory hair cells.
    Type: Application
    Filed: November 4, 2013
    Publication date: May 15, 2014
    Applicants: MASSACHUSETTS EYE AND EAR INFIRMARY, GENESYS RESEARCH INSTITUTE
    Inventors: Mark A. Parker, Albert Edge
  • Publication number: 20140134134
    Abstract: The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R.
    Type: Application
    Filed: October 9, 2013
    Publication date: May 15, 2014
    Inventors: GRANT MCFADDEN, JOHN BARRETT, MARIANNE STANFORD
  • Publication number: 20140134725
    Abstract: Synthetic surfaces suitable for culturing stem cell derived cardiomyocytes contain acrylate polymers formed from one or more acrylate monomers. The acrylate surfaces, in many cases, are suitable for culturing stem cell derived cardiomyocytes in chemically defined media.
    Type: Application
    Filed: September 17, 2013
    Publication date: May 15, 2014
    Applicant: Geron Corporation
    Inventors: Christopher Bankole Shogbon, Yue Zhou, Ralph Brandenberger
  • Publication number: 20140134722
    Abstract: The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided.
    Type: Application
    Filed: June 17, 2010
    Publication date: May 15, 2014
    Inventor: Alexey Ryazanov
  • Publication number: 20140134195
    Abstract: The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.
    Type: Application
    Filed: April 18, 2012
    Publication date: May 15, 2014
    Applicant: University of Washington through its Center for Commercialization
    Inventor: David W. Russell
  • Publication number: 20140134728
    Abstract: The present invention relates to a method for adjusting the expression of the mitochondrial genome in a human cell comprising a step consisting of modulating the expression of a least one mi RNA selected from the group consisting of hsa-mi R-1973, hsa-mi R-1275, hsa-mi R-494, hsa-mi R-513a-5p, hsa-mi R-1246, hsa-mi R-328, hsa-mi R-1908, hsa-mi R-1972, hsa-mi R-1974, hsa-mi R-1977, hsa-mi R-638, hsa-mi R-1978 and hsa-mi R-1201.
    Type: Application
    Filed: June 1, 2012
    Publication date: May 15, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Alexandra Henrion-Caude, Simonetta Bandiera, Stanislas Lyonnet
  • Publication number: 20140134726
    Abstract: Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed.
    Type: Application
    Filed: October 29, 2013
    Publication date: May 15, 2014
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel Edward Baetge
  • Publication number: 20140134724
    Abstract: A culture medium for human mesenchymal stem cells (hMSC) includes a mesenchymal stem cell basal medium; human leucocyte/platelet coat lysate; insulin; sodium selenite; ethanolamine; and basic fibroblast growth factor. This culture medium is effective for growing hMSC lines, including those which do not grow in culture medium normally used for this type of cell.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 15, 2014
    Applicant: Grifols, S. A.
    Inventors: Jose Maria DIEZ CERVANTES, Rodrigo Gajardo Rodriguez
  • Patent number: 8722405
    Abstract: The present disclosure is directed to the development of compositions, such as extracellular matrices, and processes for using the same, for culturing stem cells in vitro in an undifferentiated state. In this regard, it has been discovered that when pluripotent mouse and human embryonic stem cells are cultured on plates coated with recombinant laminin-10 (laminin-511) or laminin-5 (laminin-322), or their functional domains, the embryonic stem cells proliferated and maintained their pluripotency.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: May 13, 2014
    Inventors: Karl Tryggvason, Anna Domogatskaya, Sergey Rodin
  • Patent number: 8722034
    Abstract: Methods for treating Alzheimer's disease, or the symptoms of Alzheimer's disease, are provided. Some embodiments are to methods for treatment comprising administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells, such as cell derivatives. Some embodiments are to methods for treatment comprising hUTC. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 13, 2014
    Assignee: DePuy Synthes Products LLC
    Inventors: Anthony J. Kihm, Anna Gosiewska
  • Publication number: 20140128286
    Abstract: The present disclosure refers to a method for a specific, versatile and sensitive detection of IFN-/virus-induced genes, a method for quantifying IFN potency and activity in a pharmaceutical preparation or biological sample, a method for distinguishing between IFN- and viral induction, and/or for distinguishing between different viruses, and a method for the quantification of virus activity. Also, the invention provides the necessary molecular tools like expression active response constructs, suitable cell lines, an array to perform the method and a kit.
    Type: Application
    Filed: April 20, 2011
    Publication date: May 8, 2014
    Applicant: KING SAUD UNIVERSITY
    Inventors: Khalid S.A. Khabar, Fahad Nasser Al-Majhdi
  • Publication number: 20140127129
    Abstract: The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 8, 2014
    Applicant: Scil Proteins GmbH
    Inventors: Joerg Nerkamp, Eva Bosse-Doenecke, Arnd Steuernagel, Ulrike Fiedler, Markus Fiedler
  • Publication number: 20140127169
    Abstract: The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues.
    Type: Application
    Filed: January 24, 2012
    Publication date: May 8, 2014
    Applicants: UNIVERSITE DE STRASBOURG, STOWERS INSTITUTE FOR MEDICAL RESEARCH, ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES
    Inventors: Olivier Pourquie, Matthias Wahl, Jerome Chal
  • Patent number: 8715959
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: May 6, 2014
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Publication number: 20140120156
    Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
    Type: Application
    Filed: September 6, 2013
    Publication date: May 1, 2014
    Inventors: Vincent Craig BOND, Michael POWELL, MingBo HUANG, Syed ALI
  • Publication number: 20140120616
    Abstract: The present invention discloses protein fragment including a cell binding region of fibronectin and methods of using the same for cell culture. Additionally, surfaces modified with such protein fragment and compositions including the same are provided. Desirably, such surfaces allow various cells to adhere thereto yet avoid issues associated with animal-derived products.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 1, 2014
    Applicant: CORNING INCORPORATED
    Inventors: Deepa Saxena, Himabindu Nandivada
  • Publication number: 20140120091
    Abstract: The present invention provides improved fusion proteins for therapy of autoimmune and cardiovascular disease.
    Type: Application
    Filed: October 31, 2013
    Publication date: May 1, 2014
    Inventors: Jeffrey A LEDBETTER, Martha LEDBETTER, Vince MONTES, Alan CHAIT, Sonya SLATER